BioAtla Reports Fourth Quarter and Full Year 2022 Financial
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...
Source: globenewswire.com
Are Intolerant News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Are Intolerant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Are Intolerant Today - Breaking & Trending Today
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- Cleared dose-limiting toxicity observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma cohort readout in 2H23 - Initiated the potentially... | March 23, 2023
Source: marketscreener.com
AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...
Source: prnewswire.com
AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)
A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance standards of...
Source: prnewswire.com
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for...
Source: prnewswire.com